|  |
| --- |
|  |

|  |
| --- |
| **"Investigator experience"** |

|  |  |
| --- | --- |
|

|  |
| --- |
|  ROGER S. GAMMON, M.D.Principal Investigator:ENTICES – Enoxaparin and Ticlopidine after Elective Stenting (multi-center, randomized trial). Sponsors: Rhone Poulenc Rorer & Mallinckrodt.PURSUIT – Platelet IIb/IIIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial (10,948 patient, multi-center, randomized trial). Sponsors: Cor Therapeutics Inc., & Schering Plough Corporation.TECBEST – Transluminal Extraction Catheter Before Stent (500 patient, multi-center, randomized trial).  Sponsor: University of Alabama at Birmingham.PARAGON– Paragon Stent Trial (1,000 patient, multi-center, randomized trial).  Sponsor: Progressive Angioplasty Systems, Inc.WIZARD – Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders (3300 patient, multi-center, randomized trial). Sponsor: Pfizer, Inc.EXCITE – Evaluation of Xemilofiban in Controlling Thrombotic Events (multi-center, randomized trial).**Sponsor: Searle.**CADILLAC – Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (2,000 patient, multi-center, randomized trial). Sponsors: Advanced Cardiovascular Systems, Inc. & Lilly Research Laboratories.PARAGON B - Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (5,200 patient, multi-center, randomized trial). Sponsor: F. Hoffmann-La Roche, Ltd.AMISTAD II - Acute Myocardial Infarction Study of Adenosine (2,100 patient, multi-center, randomized trial). Sponsor: Medco Research, Inc. TRAFFIC – Therapeutic Angiogenesis with FGF for Intermittent Claudication (180 patient, multi-center, randomized trial). Sponsor: Chiron Corporation.PRESTO – Prevention of Restenosis with Tranilast and its Outcome (11,500 patient, multi-center, randomized trial). Sponsor: SmithKline Beecham Pharmaceuticals.CURE – Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (9,000 patient, multi-center, randomized trial). Sponsors: Sanofi & Bristol Myers Squibb.ATBAT – Anticoagulant Therapy with Bivalirudin to Assist in the performance of percutaneous coronary intervention in patients with heparin-induced Thrombocytopenia (100 patient, multi-center, open-label trial). Sponsor: The Medicines Company.SAFER – Saphenous vein graft Angioplasty Free of Emboli Randomized Study (800 patient, multi-center, randomized trial). Sponsor: PercuSurge Inc.PIPI – Platelet Inhibition in Peripheral Intervention (25 patient, single center, open-label trial).  Sponsor: Merck & Company, Inc.CHESS – Comparitive HDL Efficacy and Safety Study (900 patient, multi-center, randomized trial).   Sponsor: Merck & Company, Inc.REPLACE – A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events (7,000 patient, multi-center, randomized trial) Sponsor: The Medicines Company.Effect of Ad5FGF-4 on Myocardial Perfusion Defect Size and Safety in Patients with Stable Angina Study(50 patient, multi-center, randomized trial). **Sponsor: Berlex Laboratories.** SYNERGY – A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (8,000 patient, multi-center, randomized trial). Sponsor: Aventis Pharmaceutical Products, Inc.DELIVER -  Evaluation of the RX ACHIEVE™ drug coated coronary stent system in the treatment of patients with de novo native coronary artery lesions (1,042 patient, multi-center, randomized trial).  Sponsor:  Advanced Cardiovascular Systems (ACS) / Guidant Corporation.Pre-CHILL - Evaluation of the safety and feasibility of the CVSi Cryoplasty System in patients undergoing percutaneous treatment of de novo and in-stent restenosis lesions in native coronary arteries (70 patient, multi-center, open-label trial).  Sponsor: CryoVascular Systems Inc.PRIDE - Protection during saphenous vein graft intervention to prevent distal embolization (800 patient, multi-center, randomized trial).  Sponsor: Kensey Nash Corporation.Effect of Ad5FGF-4 on Exercise Tolerance and Safety in Patients with Stable Angina Study (450 patient, multi-center, randomized trial). Sponsor: Berlex Laboratories.REPLACE-2 - A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events, Part 2 (6,000 patient, multi-center, randomized trial) Sponsor: The Medicines Company.GREAT – Guided Radio Frequency Energy Ablation of Total Occlusions Using the Safe-Cross Radio Frequency Total Occlusion Crossing System (400 patient, multi-center, randomized trial). Sponsor: IntraLuminal Therapeutics, Inc.Rosuvastatin 91 – A 48 Week Open-Label, Non-Comparative, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidemia.  Sponsors include: Astra ZenecaCVSi Peripheral Balloon Catheter System Safety Registry (100 patient multicenter non-randomized registry).  Sponsors Include: CryoVascular Systems, Inc.GRIP – Guided Radio Frequency in Peripheral Total Occlusions (50 patient multicenter non-randomized registry) Sponsors include: IntraLuminal Therapeutics, Inc.PREVAIL – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BO-653 in Prevention of Post-Angioplasty Restenosis in Stented Lesions. (600 patient, randomized trial). Sponsor: Chugai Pharmaceutical Co., Ltd.ARISE  – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AGI-1067 in Reducing Cardiovascular Events in Patients with CAD. (4000 patient, randomized trial). Sponsor: AtheroGenics, Inc. TALON – A Prospective, Multi-Center, Observational Outcomes Database Registry.  Sponsors include: FoxHollow.ACUITY – A Randomized Comparison of Angiomax vs. Lovenox in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-segment Elevation (13,800 patient, randomized, multicenter trial) Sponsors include: The Medicines Company.COMBAT – A Non-Randomized Registry Study Using the FOXHOLLOW Coronary Debulking Catheter System in the Treatment of Bifurcation Lesions in Native Coronary Arteries (250 patient multicenter trial) Sponsors include: FOXHOLLOW.TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (13,000 patient Multi-Center Trial) Sponsors include: Eli Lilly and CompanyCOSTAR II – Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial (1700 patient, multicenter, randomized trial) Sponsors include: Conor Medsystems.SPIRIT III – A Clinical Evaluation of the XIENCE™ V Everolimus Coronary Stent System in the Treatment ofSubjects with de novo native Coronary Artery Lesions (1002 patient Multi-Center Trial) Sponsors include:Advanced Cardiovascular Systems, Inc. (ACS), A Subsidiary of Guidant Corporation.ACROSS-Cypher – Approaches to Chronic Occlusions with Sirolimus Stents-Cypher (250 patient Multi-CenterTrial) Sponsors include: David Kandzari, M.D. / Duke University Medical Center.CAPTURE – Carotid RX ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events(500 patient, multi-center, observational, post-approval trial) **Sponsors include: Guidant Corporation**TALON Registry ACE-I Sub-Study – Patients with bilateral disease initiated with an Ace-Inhibitor.  Sponsors include: FoxHollowTALON Registry Circulating Markers Sub-Study – Patients with long occlusions with high grade stenosis and high volume of plaque removed.  Sponsors include: FoxHollow RED-TAIL – Registry of SFA Bilateral Disease Treated with the SilverHawk System. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollowMERLIN – Multiple Lesions from a Unilateral Extremity Treated with SilverHawk in a Single Procedure. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollowOSIRIS – A Phase 1 randomized, double-blind, placebo-controlled, dose-escalation, multi-center study to determine the safety of intravenous ex-vivo cultured adult human mesenchymal stem cells following acute myocardial infarction. Sponsors include Osiris Therapeutics, Inc.BOOMERANG – Boomerang Wire Vascular Access Management Trial IIFOCUS – Follow up Of Clinical Outcomes: The Long-term AGI-1067 plus Usual Care Study (Patients that wish to continue from the ARISE Study)  Sponsors include: AtheroGenics, Inc.LEAP – A Two-part, Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Effects of Simvistatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease.PATRICIA – A Multi-center, Randomized, Open-Label Trail of Intra-Renal Fenoldopam Mesylate Vs. Intravenous Sodium Bicarbonate and Oral N-acetlycysteine in Patients at High Risk for Contrast Induced Nephropathy Undergoing Peripheral Vascular InterventionCHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) Sponsors include: The Medicines Company.BROADWING- “Biological Waste MateRial and Outcomes Analysis of Lower Extremity Peripheral Disease Treated With the SIlverHawk™ Plaque ExcisioN System: A Tissue and Data ReGistry”  FOXHOLLOW NIGHTHAWK – Evaluation of the NightHawk peripheral excision system for patients with infrainguinal lesions.  (20 patient, non-randomized, multicenter trial)  Sponsors include: FoxHollow Technologies, Inc.EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) Sponsors include: Momenta Pharmaceuticals.XIENCE V – XIENCE V USA Post-Approval Study (5,000 patient, prospective, open-label, multi-center, observational, single-arm registry)  **Sponsors include: Abbott Cardiovascular Systems, Inc.**ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novoLesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multi-center, open-label trial)  **Sponsors include: Medtronic.**OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial).  Sponsors include: Osiris Therapeutics. GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study)  Sponsors include: Accumetrics. PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study)  Sponsors include: Boston Scientific. Definitive Ca++ – SilverHawk LS-C with the SpiderFX  in lower extremity PAD undergoing plaque excision.  (102 patient, prospective, multi-center, non-randomized, single-arm study)  Sponsors include: EV3.Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.  (500 Patient, Prospective, two-arm, open-label, multi-center Registry)  Sponsors include: Abbott Cardiovascular Systems Inc.SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study)  **Sponsors include: GlaxoSmithKline.** BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe PAD (152 patients, Double-Blind, Placebo-Controlled, Multi-Center Trial) Sponsors include: Biomet Biologics. CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Multi-center, Non-randomized trial) Sponsors include: Avinger.DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions.  20,645 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: HCRI.Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) Sponsors include: Lutonix, Inc.RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized, Trial) Sponsors Include: Cardiva.PreSERVE – AMI - Intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.  (160 patient, Prospective, Randomized, Double Blinded, Placebo Controlled Trial) Sponsors Include: Amorcyte. REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification  (30,000 Patient, Multi-center, Worldwide, Randomized Trial)  Sponsors include: Oxford University, The TIMI Group and Merck. Lutonix BTK – Lutonix Drug Coated Balloon vs. Standard Balloon  Angioplasty for Treatment of Below-the-Knee(BTK) Arteries  (320 Patient, Prospective, Multicenter, Single Blind, Randomized, Controlled Trial).  **Sponsors include: C.R. Bard Inc. | Lutonix** Gene Expression – Gene expression profiling in cardiovascular diseases (30 patient, Single-center Trial)  Sponsors Include: NIH, Aaron B. Baker, Ph.D. UT Austin.Sub-Investigator:1.            AID – Angiography versus IVUS directed coronary stent placement; effect on long term clinical outcome. (multi-center, randomized trial). Sponsors: Scripps Research Foundation & Boston Scientific/SciMed.2.            ACUTE – Assessment of Cardioversion utilizing Transesophageal Echocardiography (2,900 patient, multi-center, randomized trial). Sponsors: National Institute of Health & Cleveland Clinic Foundation.3.            MERIT – Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (multi-center, randomized trial). Sponsor: Astra Zeneca.4.            VAL-HeFT - Valsartan in Heart Failure Trial (4,310 patient, multi-center, randomized trial).  Sponsor: Ciba-Geigy Corporation.RAFT - Rythmol® SR in Atrial Fibrillation Trial (450 patient, multi-center, randomized trial).  Sponsor: Knoll Pharmaceuticals, Inc.5.            IMPRESS – Inhibition of Metallo Protease by BMS – 1867 in a randomized exercise and symptoms study (532 patient, multi-center, randomized trial). Sponsor: Bristol-Myers Squibb.6.            GENECARD – Genetics of Early Onset Cardiovascular Disease (multi-center, registry trial).7.            Sponsor: Duke University Medical Center, Center of Human Genetics.8.            TNT – Treating to New Targets (8,600 patient, multi-center, randomized trial). Sponsors: Parke-Davis & Pfizer, Inc.9.            SPORTIF V: Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation  (3,000 patient, multi-center, randomized trial). Sponsor: Astra Zeneca.10.          NOET - Evaluation of the diagnostic potential of intravenously administered TcN-NOET to identify coronary artery disease during exercise and resting conditions by using gated myocardial SPECT imaging (291 patient, multi-center, open-label trial).  Sponsor: CIS-US Inc.11.          I-PRESERVE – Irbesartan in Heart Failure With Preserved Systolic Function (3600 multicenter, randomized trial)  Sponsors Include: Bristol-Myers Squibb and Sanofi-Synthelabo.12.          CVT 5131 – A Randomized, Double-Blind, Study of Intravenous CVT-3146 vs. Adenosine in Patients Undergoing Stress Myocardial Perfusion Imaging (855 patient multicenter trial)  Sponsors include: CV Therapeutics, Inc.13.          AMADEUS – A Non-inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Idraparinux with Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patient with Atrial Fibrillation (600 patient, multicenter, randomized trial) Sponsors include: Organon14.          IMPROVE- IT – IMProve Reduction of Outcomes: Vytorin Efficacy International Trial (10,000 patient, multicenter, double-blind, randomized trial) Sponsors include: Schering-Plough Research Institute.15.          RELY – Randomized, Evaluation of Long term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexialte with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-center, Parallel-group, Non-inferiority Trial.  (15,000 patient, randomized trial).  Sponsors include Boehringer Ingelheim.16.          PLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter, randomized, double-17.          blind trial) Sponsors include: AstraZeneca.18.          CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial)  Sponsors include; Abbott Vascular19.          TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind,  placebo-controlled, multinational trial) Sponsors include: Schering-Plough Research Institute.20.          STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial).  Sponsors include: Cordis.21.          SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease.  (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial)  Sponsors include:  Idev Technologies Inc.22.          RELY-Able – Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RE-LY Trial.  Sponsors include: Boehringer Ingelheim23.          DAL-OUTCOMES – RO4607381 on cardiovascular  risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (15,600 patient, double-blind, randomized, placebo-controlled study) Sponsors include: Hoffman La-Roche, Inc. 24.          PEGUSUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  Sponsors include AstraZeneca  25.          PHOENIX - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (10,900 patient, randomized, double blind, placebo-controlled) Sponsors Include: The Medicines Company.26.          SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). Sponsors include: GlaxoSmithKline (GSK)27.          Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation.  (704 Patient, Multi-center, Single-Blind, Randomized Trial)  Sponsors include: Tryton Medical, Inc.28.          CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral and popliteal29.          arteries. (114 patient Prospective, Multi-center, Non-randomized Trial)  Sponsors include: Avinger. 30.          Symplicity HTN-3 – Renal Denervation in Patients with Uncontrolled Hypertension  (1060 Patient, Multi-center, Blinded, Randomized Trial)  Sponsors include: Medtronic Ardian. 31.          EXCEL – Evaluation of  Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of  Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)  Sponsors include: Abbott Vascular. 32.          ARTISAN - iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension. (138 Prospective, Multi-center, Single-arm Trial)  Sponsors Include: Atrium Medical Corporation. 33.          Odyssey - SAR236553/REGN727 versus Placebo on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.  (18,000 patient, Randomized, Double-Blind Placebo-Controlled Trial)  Sponsors Include: Sanofi. 34.          ePAD - Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention-edoxaban in Peripheral Arterial Disease.  (200 patient Randomized, Open-Label, Parallel-Group, Multi-Center Trial) Sponsors Include: Daiichi Sankyo. 35.          Ilumien – Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  ( 500 patient, Observational Trial)  Sponsors Include: St. Jude. 36.          EHIT – Retrospective Study of Effects of Anti-coagulation Therapy on Great Saphenous Vein Ablation  (Open-ended, Single-center, Retrospective Trial)  Sponsors Include: Mark Picone, DO, Austin Heart PLLC.  FRANK  J.  ZIDAR,  M.DPrincipal Investigator: Effect of the Platelet ADP Receptor Antagonist, Clopidogrel, on Platelet and Serum Markers of Inflammation in Patients Undergoing Percutaneous Coronary Intervention; internally funded by the Cleveland Clinic Foundation.Effect of the Platelet ADP Receptor Antagonist, Clopidogrel, on Early Platelet and Serum markers of Inflammation and Aggregation; internally funded by the Cleveland Clinic Foundation.CASES-PMS- Carotid Artery Stenting with Emboli Protection Surveillance – Post Market Study; funded by Cordis, a Johnson & Johnson company.EXACT – Emboshield and Xact Post Approval Carotid Stent Trial (Multi-center, Observational, Single Arm, Post-Approval Study); Sponsors include: Abbott Vascular DevicesSWIFT – Femeropopliteal Disease Treated With the SilverHawk Plaque Excision System: A Non-Randomized Registry with Duplex Ultrasound Follow Up At Twelve MonthsACT I – Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease (1540 patient, multicenter, randomized trial) Sponsors include: Abbott VascularPLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter, randomized, double-blind trial) **Sponsors include: AstraZeneca.** CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial)  Sponsors include; Abbott VascularPROTECT – Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (320 patient, multicenter, non-randomized trial) Sponsors include: Abbott VascularNIGHTHAWK – Evaluation of the NightHawk peripheral excision system for patients with infrainguinal lesions.  (20 patient, non-randomized, multicenter trial)  Sponsors include: FoxHollow Technologies, Inc.RBM – Luminex xMAP (multianalyte profile) to diagnose ACS patients using blood biomarker profiles (200 patient, single-center study)  Sponsors include: Rules Based Medicine.  SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease.  (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial)  Sponsors include:  Idev Technologies Inc.STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial).  **Sponsors include: Cordis.** Symplicity HTN-3 – Renal Denervation in Patients with Uncontrolled Hypertension  (1060 Patient, Multi-center, Blinded, Randomized Trial)  Sponsors include: Medtronic Ardian. EXCEL – Evaluation of  Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of  Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)  Sponsors include: Abbott Vascular. ARTISAN - iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension. (138 Prospective, Multi-center, Single-arm Trial)  Sponsors Include: Atrium Medical Corporation. SAPPHIRE – Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire for patients at high risk for carotid endarterectomy.  (21,000 patient, Multi-Center, Prospective, Observation Trial).  **Sponsors Include: Cordis** Ilumien I – Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  (500 patient, Observational Trial)  Sponsors Include: St. Jude. Partner II / IIA / IIB / S3 / S3i  – SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems in Intermediate and High Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery.  (500 patient, Prospective, Randomized, Multi-center Trial)  Sponsors Include: Edwards Life. PORTICO – Transcatheter heart valve therapy vs. commercially available trans-catheter valve(CAV) in patients with symptomatic severe native aortic stenosis, who are considered high or extreme surgical risk.  (1610 Patient, Prospective, Multi-center, Randomized Trial)  Sponsors include: St. Jude.Ilumien III – Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  ( 500 patient, Observational Trial)  Sponsors Include: St. Jude.  Sub-Investigator:A Pilot Study to Identify Novel Protein Biomarkers of Atheromatous Plaques in Patients with Ischemic Heart Disease Undergoing Elective Percutaneous Intervention with Stent Placement; funded by Bristol-Myers Squibb Pharmaceutical Research Institute.OSIRIS – A Phase 1 randomized, double-blind, placebo-controlled, dose-escalation, multi-center study to determine the safety of intravenous ex-vivo cultured adult human mesenchymal stem cells following acute myocardial infarction. Sponsors include Osiris Therapeutics, Inc.RED-TAIL – Registry of SFA Bilateral Disease Treated with the SilverHawk System. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollowMERLIN – Multiple Lesions from a Unilateral Extremity Treated with SilverHawk in a Single Procedure. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollowCAPTURE – Carotid RX ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events (500 patient, multi-center, observational, post-approval trial) Sponsors include: Guidant CorporationSPIRIT III – A Clinical Evaluation of the XIENCE™ V Everolimus Coronary Stent System in the Treatment of Subjects with de novo native Coronary Artery Lesions (1002 Patient Multi-Center Trial) Sponsors include: Advanced Cardiovascular Systems, Inc. (ACS), A Subsidiary of Guidant CorporationRELY – Randomized, Evaluation of Long term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexialte with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-center, Parallel-group, Non-inferiority Trial.  (15,000 patient, randomized trial).  **Sponsors include Boehringer Ingelheim.**TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (13,000 patient Multi-Center Trial) Sponsors include: Eli Lilly and Company ACROSS-Cypher: Approaches to Chronic Occlusions with Sirolimus Stents  for Total Occlusion of Coronary Arteries; funded by Cordis, a Johnson & Johnson company.COSTAR II Cobalt Chromium Stent with Antiproliferative for Restenosis; funded by Conor Medsystems.ECLIPSE Effect of 600mg Pretreatment Clopidogrel Loading on Platelet Inhibition During PCI with Sequential Abciximab Experience. The ECLIPSE Study; internally funded by the Cleveland Clinic Foundation.LEAP – A Two-part, Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Effects of Simvistatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease.PATRICIA – A Multi-center, Randomized, Open-Label Trail of Intra-Renal Fenoldopam Mesylate Vs. Intravenous Sodium Bicarbonate and Oral N-acetlycysteine in Patients at High Risk for Contrast Induced Nephropathy Undergoing Peripheral Vascular InterventionBROADWING- “Biological Waste MateRial and Outcomes Analysis of Lower Extremity Peripheral Disease Treated With the SIlverHawk™ Plaque ExcisioN System: A Tissue and Data ReGistry”  FOXHOLLOWCHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) **Sponsors include: The Medicines Company.**TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind,  placebo-controlled, multinational trial) Sponsors include: Schering-Plough Research Institute.EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) **Sponsors include: Momenta Pharmaceuticals.**XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) **Sponsors include: Abbott Cardiovascular Systems, Inc.**ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novoLesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multi-center, open-label trial)  **Sponsors include: Medtronic.** OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial).  **Sponsors include: Osiris Therapeutics.**GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study)  **Sponsors include: Boston Scientific.**PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study)  **Sponsors include: Boston Scientific.**Definitive Ca++ – SilverHawk LS-C with the SpiderFX  in lower extremity PAD undergoing plaque excision.  (102 patient, prospective, multi-center, non-randomized, single-arm study)  **Sponsors include: EV3.**Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.  (500 Patient, Prospective, two-arm, open-label, multi-center Registry)  **Sponsors include: Abbott Cardiovascular Systems Inc.**SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study)  **Sponsors include: GlaxoSmithKline.** RELY-Able – Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RE-LY Trial.  **Sponsors include: Boehringer Ingelheim.** BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe PAD (152 patient, Double-Blind, Placebo-Controlled, Multi-Center Trial) **Sponsors include: Biomet Biologics.**CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Multi-center, Non-randomized trial) **Sponsors include: Avinger.**DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions.  20,645 Patient, Multi-center, Randomized, Double-blind Trial) **Sponsors include: HCRI.**Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) **Sponsors include: Lutonix, Inc.**PEGUSUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  **Sponsors include AstraZeneca** PHOENIX - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (10,900 patient, randomized, double blind, placebo-controlled) **Sponsors Include: The Medicines Company.** RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized, Trial) **Sponsors Include: Cardiva.**SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). **Sponsors include: GlaxoSmithKline (GSK)**Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation.  (704 Patient, Multi-center, Single-Blind, Randomized Trial) **Sponsors include: Tryton Medical, Inc.**EXCEL – Evaluation of  Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of  Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)  **Sponsors include: Abbott Vascular.**CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral and poplitealarteries. (114 patient Prospective, Multi-center, Non-randomized Trial)  **Sponsors include: Avinger.**PreSERVE – AMI - Intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.  (160 patient, Prospective, Randomized, Double Blinded, Placebo Controlled Trial) **Sponsors Include: Amorcyte**.  Odyssey - SAR236553/REGN727 versus Placebo on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.  (18,000 patient, Randomized, Double-Blind Placebo-Controlled Trial)  **Sponsors Include: Sanofi.**REGULATE PCI – REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneous coronary intervention.  (13,200 patient randomized, open-label, multi-center, active-controlled trial)  **Sponsors Include: Regado Biosciences.**ePAD - Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention-edoxaban in Peripheral Arterial Disease.  (200 patient Randomized, Open-Label, Parallel-Group, Multi-Center Trial) **Sponsors Include: Daiichi Sankyo.**REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification  (30,000 Patient, Multi-center, Worldwide, Randomized Trial)  **Sponsors include: Oxford University, The TIMI Group and Merck.**Lutonix BTK – Lutonix Drug Coated Balloon vs. Standard Balloon  Angioplasty for Treatment of Below-the-Knee(BTK) Arteries  (320 Patient, Prospective, Multicenter, Single Blind, Randomized, Controlled Trial).  **Sponsors include: C.R. Bard Inc. | Lutonix** REX – REX medical closer vascular system for the management of femoral arteriotomy after percutaneous endovascular procedures.  (200 Patient, Prospective, Multi-Center, Single-Arm Trial)   **Sponsors include: Rex Medical.** ALLSTAR –Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an AnteriorMyocardial Infarction and Ischemic Left Ventricular Dysfunction.  (260 patient, Randomized, Double-Blind, Placebo-Controlled Trial).  **Sponsors include: Capricor Inc.** LATITUDE-TIMI 60 – Losmapimod to inhibit p38 MAP kinase after an acute coronary syndrome.  (25,500 Patient, Randomized, Double-Blind, Multi-center Trial)  **Sponsors include:  GlaxoSmithKline.** VISION – Pantheris Optical Coherence Tomography Imaging Atherectomy System for use in the Peripheral Vasculature.  (173 patient, non-randomized, prospective, global, single arm trial).  **Sponsors include: Avinger Inc.** SPIRE – Studies of PCSK9 Inhibition and the Reduction of vascular Events B1481022 & B1481038 (17,000 Patient, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial)  **Sponsors include: Pfizer.**MIMICS 2 – Evaluation of Safety and Effectiveness of the BioMimics 3D™ Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease (280 Patient, Prospective, Single-arm, Multi-center trial)  **Sponsors include: Veryan.**TEVA – Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP–41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology.  (1730 Patient, Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Trial).  **Sponsors include: Teva Branded Pharmaceutical Products.** SALUS – Transcatheter Aortic Valve Replacement System Pivotal Trial (912 Patient, Prospective, Randomized, Un-blinded, Multi-Center Trial).  **Sponsors include: Direct Flow Medical** MARK F. PICONE, D.O., FACC, FSCAIRESEARCH: Isolation and Extraction of Amino Acids from Blue Green Algae. State University of New York at Brockport, Dept. of Chemistry. Presented at American Chemical Society Symposium, March 1980.Renal Function and Metabolism. University of Rochester Medical Center, Dept. of Physiology. November 1981-August 1983.Support of Kidney Function by Long Chain Fatty Acids Derived from Renal Tissue. Fontaneles MS, Cohen JJ, Black A, Werheim S. American Physiological Society 1983, 234-46.Familial Idiopathic Dilated Cardiomyopathy (a case report) Picone MF, Eahr d. Presented at Regional College of Physicians meeting in Traverse City, Michigan, October 1989.Intracoronary Electrogram Monitoring During PTCA in Direction of Myocardium Viability. Picone MF, Meany B, Stone C. May 1992-1994.How Helpful is the Clinical History in Predicting the Results to Tilt Table Test? DeBuitleir M, Casteen JA, Picone MF, Bidwell D. Submitted to the 66th Scientific AHA Mtg., 1993. Principal Investigator: IMPROVE- IT – IMProve Reduction of Outcomes: Vytorin Efficacy International Trial (10,000 patient, multicenter, double-blind, randomized trial).**Sponsors include: Schering-Plough Research Institute.**BROADWING – “Biological Waste MateRial and Outcomes Analysis of Lower Extremity Peripheral Disease Treated With the SIlverHawk™ Plaque ExcisioN System: A Tissue and Data ReGistry”  FOXHOLLOWTIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind,  placebo-controlled, multinational trial) **Sponsors include: Schering-Plough Research Institute**DAL-OUTCOMES – RO4607381 on cardiovascular  risk in stable CHD patients, with a documented recent AcuteCoronary Syndrome (15,600 patient, double-blind, randomized, placebo-controlled study) Sponsors include: Hoffman La-Roche, Inc. PEGUSUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  **Sponsors include AstraZeneca**CHAMPION Phoenix – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition.  (10,900 patient, Randomized, double blind, placebo-controlled trial)  **Sponsors include: The Medicines Company.**EHIT – Retrospective Study of Effects of Anti-coagulation Therapy on Great Saphenous Vein Ablation  (Open-ended, Single-center, Retrospective Trial)  **Sponsors Include: Mark Picone, DO, Austin Heart PLLC.**Odyssey - SAR236553/REGN727 versus Placebo on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.  (18,000 patient, Randomized, Double-Blind Placebo-Controlled Trial)  **Sponsors Include: Sanofi.** Sub-Investigator:GUSTO II B – Global use of strategies to open occluded coronary arteries. 1995NICE III – Pilot study of Enoxaparin Therapy in patients with unstable angina and non Q-MI: Safety of concominant use with GP II b/III a Inhibitors. 1999-2000RAPIER – Reperfusion After Platelet Inhibition in the Emergency Rooom Tirofiban. 1999T-Wave Alternans Sub-Study of SCD-HeFT- Sponsored by Cambridge Heart, Inc. 2000-2002ENTIRE- Enoxaprin and Tnk-tPA with or without GP II b/III a inhibitor as Reperfusion strategy in S.T. elevation in M.I. 2000-2002VITAL- Vasopressin inhibition with trollvaptain (OPC-41061) long term effiency. 2002SCD-HEFT- Sudden Cardiac Death Failure Trail. 1999-2002OCTAVE- Omapatrilat cardiovascular treatment assessment versus enalapril. (co-investigator). 1999-2002Prognostic Significance of T-Wave Alternans in Patients with Congestive Heart Failure- Sponsored by the NHLBI, Cambridge Heart, Inc., and Columbia University. 2000-2002Medtronic Arrhythmia Pathway Study- **Sponsored by Medtronic, Inc. 2000-2002** SAFE “Silent Atrial Fibrillation Detection with Stored EGMs Study”- **Sponsored by Guidant Corporation. 2000-2002** IMPACT “The impact of Medical Subspecialty on Patient Compliance to Treatment”- **Sponsored by Kos Pharmaceuticals, Inc., and DuPont Pharmaceutical Company, 2000-2002**PEECH “Enhanced External Counterpulsation (EECP) in Heart Failure: a Single-Blind Controlled, Randomized Evaluation of Efficacy and Safety <Protocol Number V09901>- **Sponsored by Vasomedical, Inc. 2002**SYNERGY – A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (8,000 patient, multi-center, randomized trial). **Sponsor: Aventis Pharmaceutical Products, Inc.**GREAT – Guided Radio Frequency Energy Ablation of Total Occlusions Using the Safe-Cross Radio Frequency Total Occlusion Crossing System (400 patient, multi-center, randomized trial). **Sponsor: IntraLuminal Therapeutics, Inc.**PREVAIL – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BO-653 in Prevention of Post-Angioplasty Restenosis in Stented Lesions. (600 patient, randomized trial). **Sponsor: Chugai Pharmaceutical Co., Ltd.**PRIDE - Protection during saphenous vein graft intervention to prevent distal embolization (800 patient, multi-center, randomized trial).  **Sponsor: Kensey Nash Corporation.**GRIP – Guided Radio Frequency in Peripheral Total Occlusions (50 patient multicenter non-randomized registry) **Sponsors include: IntraLuminal Therapeutics, Inc.**ARISE  – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AGI-1067 in Reducing Cardiovascular Events in Patients with CAD. (4000 patient, randomized trial). **Sponsor: AtheroGenics, Inc.**CVT 5131 – A Randomized, Double-Blind, Study of Intravenous CVT-3146 vs. Adenosine in Patients Undergoing Stress Myocardial Perfusion Imaging (855 patient multicenter trial) **Sponsors include: CV Therapeutics, Inc.**ACUITY – A Randomized Comparison of Angiomax vs. Lovenox in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-segment Elevation (13,800 patient, randomized, multicenter trial) **Sponsors include: The Medicines Company.**TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (13,000 patient Multi-Center Trial) **Sponsors include: Eli Lilly and Company**SPIRIT III – A Clinical Evaluation of the XIENCE™ V Everolimus Coronary Stent System in the Treatment of subjects with de novo native Coronary Artery Lesions (1002 patient Multi-Center Trial) **Sponsors include: Advanced Cardiovascular Systems, Inc. (ACS), A Subsidiary of Guidant Corporation**ACROSS-Cypher – Approaches to Chronic Occlusions with Sirolimus Stents-Cypher (250 patient Multi-Center Trial) **Sponsors include: David Kandzari, M.D. / Duke University Medical Center.**CAPTURE – A post approval study of the Guidant acculink stent systems and accunet embolic protection systems (Carotid RX Acculink/Accuent Post – Approval Trial to Uncover Unanticipated and Rare Events.Costar II – Prospective, Multi-Center, Single Blind, Two-Arm, randomized, controlled, Trial of  the Conor Costar Paclitaxel – Eluting Coronary Stent System Versus the Taxus Drug Eluting Coronary Stent System in patients with de novo lesions of the native Coronary Arteries.    LEAP- A Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Simvastatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Artery Disease (Phase 0)MK0633 Ib -An Exploratory Double-Blind, Placebo Controlled, Randomized, 4 Week Oral dose Study to Evaluate the Effects of MK-0633 on Atherosclerotic Cardiovascular Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease.               MK0633  2a- A Double-Blind, Placebo-Controlled, Randomized Proof of Concept Study to Evaluate the Efficacy and Safety of MK-0633 in Men With Atherosclerotic DiseasePLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter, randomized, double-blind trial) **Sponsors include: AstraZeneca.** CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial)  **Sponsors include; Abbott Vascular**CHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) **Sponsors include: The Medicines Company.**EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) **Sponsors include: Momenta Pharmaceuticals.**XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) **Sponsors include: Abbott Cardiovascular Systems, Inc.**ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multi-center, open-label trial)  **Sponsors include: Medtronic.**OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial).**Sponsors include: Osiris Therapeutics.** GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study)  **Sponsors include: Boston Scientific.**PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study)  **Sponsors include: Boston Scientific.**Definitive Ca++ – SilverHawk LS-C with the SpiderFX  in lower extremity PAD undergoing plaque excision.  (102 patient, prospective, multi-center, non-randomized, single-arm study)  **Sponsors include: EV3.**Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.  (500 Patient, Prospective, two-arm, open-label, multi-center Registry)  **Sponsors include: Abbott Cardiovascular Systems Inc.**STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial).  **Sponsors include: Cordis.**SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease.  (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial)  **Sponsors include:  Idev Technologies Inc.**SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study) **Sponsors include: GlaxoSmithKline.**ACT I – Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease (1540 patient, multicenter, randomized trial)**Sponsors include: Abbott Vascular** CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Multi-center, Non-randomized trial) **Sponsors include: Avinger.**DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions.  20,645 Patient, Multi-center, Randomized, Double-blind Trial) **Sponsors include: HCRI.**RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized, Trial) **Sponsors Include: Cardiva.**SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). **Sponsors include: GlaxoSmithKline (GSK).**Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) **Sponsors include: Lutonix, Inc.**REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification  (30,000 Patient, Multi-center, Worldwide, Randomized Trial)  **Sponsors include: Oxford University, The TIMI Group and Merck.**CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral and popliteal arteries. (114 patient Prospective, Multi-center, Non-randomized Trial)  **Sponsors include: Avinger.**ARTISAN - iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension. (138 Prospective, Multi-center, Single-arm Trial)  **Sponsors Include: Atrium Medical Corporation.**PreSERVE – AMI - Intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.  (160 patient, Prospective, Randomized, Double Blinded, Placebo Controlled Trial) **Sponsors Include: Amorcyte.** ePAD - Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention-edoxaban in Peripheral Arterial Disease.  (200 patient Randomized, Open-Label, Parallel-Group, Multi-Center Trial) **Sponsors Include: Daiichi Sankyo.**SAPPHIRE – Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire for patients at high risk for carotid endarterectomy.  (21,000 patient, Multi-Center, Prospective, Observation Trial).  **Sponsors Include: Ilumien –** Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  (500 patient, Observational Trial)  **Sponsors Include: St. Jude.**REGULATE PCI – REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneous coronary intervention.  (13,200 patient randomized, open-label, multi-center, active-controlled trial)**Sponsors Include: Regado Biosciences.** Lutonix BTK – Lutonix Drug Coated Balloon vs. Standard Balloon  Angioplasty for Treatment of Below-the-Knee (BTK) Arteries  (320 Patient, Prospective, Multicenter, Single Blind, Randomized, Controlled Trial).  **Sponsors include: C.R. Bard Inc. | Lutonix**VISION – Pantheris Optical Coherence Tomography Imaging Atherectomy System for use in the Peripheral Vasculature.  (173 patient, non-randomized, prospective, global, single arm trial).  **Sponsors include: Avinger Inc.** REX – REX medical closer vascular system for the management of femoral arteriotomy after percutaneous endovascular procedures.  (200 Patient, Prospective, Multi-Center, Single-Arm Trial)   **Sponsors include: Rex Medical.**ALLSTAR –Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction.  (260 patient, Randomized, Double-Blind, Placebo-Controlled Trial).  **Sponsors include: Capricor Inc.** LATITUDE-TIMI 60 – Losmapimod to inhibit p38 MAP kinase after an acute coronary syndrome.  (25,500 Patient, Randomized, Double-Blind, Multi-center Trial)  **Sponsors include: GlaxoSmithKline.** SPIRE – Studies of PCSK9 Inhibition and the Reduction of vascular Events B1481022 & B1481038 (17,000 Patient, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial)  **Sponsors include: Pfizer.**MIMICS 2 – Evaluation of Safety and Effectiveness of the BioMimics 3D™ Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease (280 Patient, Prospective, Single-arm, Multi-center trial)  **Sponsors include: Veryan.**TEVA –Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP–41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology.  (1730 Patient, Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Trial). **Sponsors include: Teva Branded Pharmaceutical Products.** KUNJAN A. BHATT, M.D.Principal Investigator:MultiPoint Pacing – Efficacy of the Quadripolar CRT-D device system (with MPP feature) when compared to standard BiV pacing in patients that are indicated for a CRT-D device (506 patient, Prospective, Randomized, Double-blind, Multi-center Trial)  **Sponsors Include: St. Jude.**CardioMEMS – CardioMEMS HF System in patients with Class III Heart Failure in a commercial setting (1200 Patient, Non-Randomized, Post-Market Registry)  **Sponsors include: St. Jude Medical.**  Sub Investigator:POINT 3 – A Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive TechnologyUsing PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive Coronary Artery DiseaseII (850 patients, open label, multicenter trial) Sponsors include: POINT Biomedical Corporation.TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind,  placebo-controlled, multinational trial)**Sponsors include: Schering-Plough Research Institute.**PEGASUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  **Sponsors include AstraZeneca** SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). Sponsors include: GlaxoSmithKline (GSK). Laptop – Left Atrial Pressure Monitoring to Optimize Heart Failure (730 Patient, Multicenter, Randomized Trial). Sponsors include: St. Jude Medical.  Matthew R. Selmon, MD Principle Investigator: CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral andpopliteal arteries. (114 patient Prospective, Multi-center, Non-randomized Trial)  Sponsors include:Avinger.  Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation.  (704 Patient, Multi-center, Single-Blind, Randomized Trial)  Sponsors include: Tryton Medical, Inc. Sub-Investigator: LEAP – A Two-part, Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Effects of Simvastatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease.  Sponsors include: FoxHollow Technologies. SWIFT – Femoropoliteal Disease Treated with the SilverHawk Plaque Excision System: A Non-Randomized Registry With Duplex Ultrasound Follow–up at Twelve Months.  Sponsors include: FoxHollow Technologies. LEAP-MK0633 – A Phase-1b, Randomized, Double-blind, 4-week Trail to Evaluate the Effects of MK-0633 on Atherosclerotic Cardiovascular Disease Biomarkers in Lower Extremity Plaque Excised from Peripheral Arterial Disease Patients.  Sponsors include: Merck & Company, Inc. PLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter, randomized,double-blind trial) Sponsors include: AstraZeneca. CHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) Sponsors include: The Medicines Company. CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating OutcomesThrough Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial) Sponsors include; Abbott Vascular EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) Sponsors include: Momenta Pharmaceuticals. TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind,  placebo-controlled, multinational trial) Sponsors include: Schering-Plough Research Institute. XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) Sponsors include: Abbott Cardiovascular Systems, Inc. OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial).  Sponsors include: Osiris Therapeutics.  ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novoLesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multi-center, open-labeltrial)  Sponsors include: Medtronic.  GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study)  Sponsors include: Boston Scientific.  PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study) Sponsors include: Boston Scientific. Definitive Ca++ – SilverHawk LS-C with the SpiderFX in lower extremity PAD undergoing plaque excision.  (102 patient, prospective, multi-center, non-randomized, single-arm study)  Sponsors include: EV3. Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.  (500 Patient, Prospective, two-arm, open-label, multi-center Registry)  Sponsors include: Abbott Cardiovascular Systems Inc. STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial).  Sponsors include: Cordis. SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease.  (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial)  Sponsors include:  Idev Technologies Inc. SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study) Sponsors include: GlaxoSmithKline. DAL-OUTCOMES – RO4607381 on cardiovascular risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (15,600 patient, double-blind, randomized, placebo-controlled study) Sponsors include: Hoffman La-Roche, Inc.  BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe PAD (152 patient, Double-Blind, Placebo-Controlled, Multi-Center Trial) Sponsors include: Biomet Biologics.  CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Multi-center, Non-randomized trial) Sponsors include: Avinger. DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions.  20,645 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: HCRI. PHOENIX - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (10,900 patient, randomized, double blind, placebo-controlled) Sponsors Include: The Medicines Company. RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized, Trial) Sponsors Include: Cardiva. EXCEL – Evaluation of  Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of  Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)  Sponsors include: Abbott Vascular.  ARTISAN - iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension. (138 Prospective, Multi-center, Single-arm Trial)  Sponsors Include: Atrium Medical Corporation.  PreSERVE – AMI - Intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.  (160 patient, Prospective, Randomized, Double Blinded, Placebo Controlled Trial) Sponsors Include: Amorcyte.  ePAD - Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention-edoxaban in Peripheral Arterial Disease.  (200 patient Randomized, Open-Label, Parallel-Group, Multi-Center Trial) Sponsors Include: Daiichi Sankyo.  SAPPHIRE – Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire for patients at high risk for carotid endarterectomy.  (21,000 patient, Multi-Center, Prospective, Observation Trial).  Sponsors Include: Ilumien – Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  ( 500 patient, Observational Trial)  Sponsors Include: St. Jude.  REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification  (30,000 Patient, Multi-center, Worldwide, Randomized Trial)  Sponsors include: Oxford University, The TIMI Group and Merck. Lutonix BTK – Lutonix Drug Coated Balloon vs. Standard Balloon  Angioplasty for Treatment of Below-the-Knee (BTK) Arteries  (320 Patient, Prospective, Multicenter, Single Blind, Randomized, ControlledTrial).  Sponsors Include: C.R. Bard Inc. | Lutonix EHIT – Retrospective Study of Effects of Anti-coagulation Therapy on Great Saphenous Vein Ablation  (Open-ended, Single-center, Retrospective Trial)  Sponsors Include: Mark Picone, DO, Austin Heart PLLC. REGULATE PCI – REG1 anticoagulation system compared to bivalirudin in patients undergoingpercutaneous coronary intervention.  (13,200 patient randomized, open-label, multi-center, active-controlled trial)  Sponsors Include: Regado Biosciences.  VISION – Pantheris Optical Coherence Tomography Imaging Atherectomy System for use in the peripheral Vasculature.  (173 patient, non-randomized, prospective, global, single arm trial).  Sponsors include: Avinger Inc.  REX – REX medical closer vascular system for the management of femoral arteriotomy afterpercutaneous endovascular procedures.  (200 Patient, Prospective, Multi-Center, Single-Arm Trial)Sponsors include: Rex Medical.  Location – Heart Hospital.  81 Patients enrolled. ALLSTAR –Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an AnteriorMyocardial Infarction and Ischemic Left Ventricular Dysfunction.  (260 patient, Randomized, Double-Blind, Placebo-Controlled Trial).  Sponsors include: Capricor Inc.  MIMICS 2 – Evaluation of Safety and Effectiveness of the BioMimics 3D™ Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease (280 Patient, Prospective, Single-arm, Multi-center trial)  Sponsors include: Veryan.  TEVA –Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP–41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology.  (1730 Patient, Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Trial).  Sponsors include: Teva Branded Pharmaceutical Products.  JUHANA KARHA, M.D. Principle Investigator: ePAD - Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention-edoxaban in Peripheral Arterial Disease.  (200 patient Randomized, Open-Label, Parallel-Group, Multi-Center Trial) Sponsors Include: Daiichi Sankyo.  Sub-Investigator:SAPPHIRE WW ZILVER PTX CAPTURE 2 – Carotid RX ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events (multi-center, observational, post-approval trial) Sponsors include: Guidant Corporation ACT I – Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease (1540 patient, multicenter, randomized trial) Sponsors include: Abbott Vascular CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial)  Sponsors include; Abbott Vascular XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) Sponsors include: Abbott Cardiovascular Systems, Inc. OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial).  Sponsors include: Osiris Therapeutics.  GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study)  Sponsors include: Boston Scientific.  PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study)  Sponsors include: Boston Scientific.  Definitive Ca++ – SilverHawk LS-C with the SpiderFX  in lower extremity PAD undergoing plaque excision.  (102 patient, prospective, multi-center, non-randomized, single-arm study)  Sponsors include: EV3.Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.  (500 Patient, Prospective, two-arm, open-label, multi-center Registry)  Sponsors include: Abbott Cardiovascular Systems Inc. STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial).  Sponsors include: Cordis.SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease.  (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial)  Sponsors include:  Idev Technologies Inc. SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study)  Sponsors include: GlaxoSmithKline. BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe PAD (152 patient, Double-Blind, Placebo-Controlled, Multi-Center Trial) Sponsors include: Biomet Biologics.  CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Multi-center, Non-randomized trial) Sponsors include: Avinger. DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions.  20,645 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: HCRI. Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) Sponsors include: Lutonix, Inc. PEGUSUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  Sponsors include AstraZeneca   PHOENIX - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (10,900 patient, randomized, double blind, placebo-controlled) Sponsors Include: The Medicines Company. RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized, Trial) Sponsors Include: Cardiva. SAVOR TIMI 53 - Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus.  (12,000 Patient, Multi-Center, Double-Blind, Placebo-Controlled Trial) Sponsors include: AstraZeneca & Bristol Myers Squibb. SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). Sponsors include: GlaxoSmithKline (GSK) Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation.  (704 Patient, Multi-center, Single-Blind, Randomized Trial) Sponsors include: Tryton Medical, Inc. CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral and poplitealarteries. (114 patient Prospective, Multi-center, Non-randomized Trial)  Sponsors include: Avinger.  EXCEL – Evaluation of  Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of  Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)  Sponsors include: Abbott Vascular.  ARTISAN - iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension. (138 Prospective, Multi-center, Single-arm Trial)  Sponsors Include: Atrium Medical Corporation.  EUCLID – Ticagrelor with clopidogrel treatment in patients with established Peripheral Artery Disease.  (950 patient, Randomized, Double-Blind, Parallel-Group, Multi-Center Trial)  Sponsors Include: Astra Zeneca.  PreSERVE – AMI - Intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.  (160 patient, Prospective, Randomized, Double Blinded, Placebo Controlled Trial) Sponsors Include: Amorcyte.  Partner II/IIA/IIB/S3/S3i  – SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems in Intermediate and High Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery.  (500 patient, Prospective, Randomized, Multi-center Trial)  Sponsors Include: Edwards Life.  REGULATE PCI – REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneous coronary intervention.  (13,200 patient randomized, open-label, multi-center, active-controlled trial)  Sponsors Include: Regado Biosciences.  SAPPHIRE – Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire for patients at high risk for carotid endarterectomy.  (21,000 patient, Multi-Center, Prospective, Observation Trial).  Sponsors Include: Ilumien – Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention  ( 500 patient, Observational Trial)  Sponsors Include: St. Jude.  REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification  (30,000 Patient, Multi-center, Worldwide, Randomized Trial)  Sponsors include: Oxford University, The TIMI Group and Merck.  Lutonix BTK – Lutonix Drug Coated Balloon vs. Standard Balloon  Angioplasty for Treatment of Below-the-Knee(BTK) Arteries  (320 Patient, Prospective, Multicenter, Single Blind, Randomized, Controlled Trial).  SponsorsInclude: C.R. Bard Inc. | Lutonix REX – REX medical closer vascular system for the management of femoral arteriotomy after percutaneousendovascular procedures.  (200 Patient, Prospective, Multi-Center, Single-Arm Trial)   Sponsors include: RexMedical.  ALLSTAR –Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an AnteriorMyocardial Infarction and Ischemic Left Ventricular Dysfunction.  (260 patient, Randomized, Double-Blind,Placebo-Controlled Trial).  Sponsors include: Capricor Inc.  PORTICO – Transcatheter heart valve therapy vs. commercially available trans-catheter valve(CAV) in patients with symptomatic severe native aortic stenosis, who are considered high or extreme surgical risk.  (1610 Patient, Prospective, Multi-center, Randomized Trial)  Sponsors include: St. Jude.  MIMICS 2 – Evaluation of Safety and Effectiveness of the BioMimics 3D™ Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease (280 Patient, Prospective, Single-arm, Multi-center trial)  Sponsors include: Veryan.  TEVA –Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP–41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology.  (1730 Patient, Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Trial).  Sponsors include: Teva Branded Pharmaceutical Products.  CRAIG SIEGEL, M.D., FACC Principal Investigator: PURSUIT - PURSUIT – Platelet IIb/IIIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial (10,948 patient, multi-center, randomized trial). Sponsors: Cor Therapeutics Inc., & Schering Plough Corporation. TIMI 30 – PROTECT -  A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents (900 patient, multi-center, randomized trial). Sponsor: Millennium Pharmaceuticals. TIMI 38 - TRITON-TIMI 38 – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo percutaneous Coronary Intervention (13,000 patient, randomized, multicenter trial) Sponsors include: Eli Lilly and Company.  31 patients enrolled. ATHENA – ATHENA Trial – A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400mg bid for the prevention of cardiovascular Hospitalization for death from any cause in PatiENts with Atrial fibrillation/atrial flutter (4,628 patient, randomized, multi-center trial). Sponsor: Sanofi-Aventis. IMPROVE-IT - IMPROVE-IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMProved Reduction of Outcomes:  Vytorin Efficacy International Trial).  RED-HF  - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia (2,600 patient, randomized, multi-center trial). Sponsor: Amgen. EARLY ACS - Early ACS – Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome:  A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome. Dal-Outcomes – To evaluate the effects of dalcetrapib in stable CHD patients with recent ACS (15,600  patient, double-blind, randomized, multicenter study)  Sponsors include: Hoffman La Roche, Inc.SOLSTICE - A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size and cardiac function in subjects with myocardial infarction without ST-segment elevation.  Sponsor include:  GlaxoSmithKline SOLID TIMI 52 - A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). Sponsors include: GlaxoSmithKline (GSK). PEGUSUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome.  (13,500 patient, Randomized, Double-blind, Placebo-controlled trial)  Sponsors include AstraZeneca   Champion PHOENIX - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (10,900 patient, randomized, double blind, placebo-controlled) Sponsors Include: The Medicines Company. EVOLVE II – SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System vs. Promus ElementStent System for the Treatment of Atherosclerotic Lesion(s).  (1684 patient, Prospective, Multicenter Trial).Sponsors Include: Boston Scientific.  REGULATE PCI – REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneouscoronary intervention.  (13,200 patient randomized, open-label, multi-center, active-controlled trial)  SponsorsInclude: Regado Biosciences.  LATITUDE-TIMI 60 – Losmapimod to inhibit p38 MAP kinase after an acute coronary syndrome.  (25,500 Patient, Randomized, Double-Blind, Multi-center Trial)  Sponsors include: GlaxoSmithKline.  Sub-Investigator: EUCLID – Ticagrelor with clopidogrel treatment in patients with established Peripheral Artery Disease.  (950patient, Randomized, Double-Blind, Parallel-Group, Multi-Center Trial)  Sponsors Include: Astra Zeneca.  ORBIT II – Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (15,000 patient, Multi-center, Prospective Registry).  Sponsors Include: Jansen Scientific Affairs.  |

 |